Trials / Completed
CompletedNCT00614614
Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014
Immunogenicity and Safety Study of a Booster Dose of GSK Biologicals' Meningococcal Vaccine 134612 Given at 12-15 Months of Age or at 15-18 Months of Age (Co-administered With Infanrix®) in Primed Healthy Toddlers.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,558 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 6 Weeks – 12 Weeks
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to characterize the immunogenicity \& safety of a booster dose of GSK Biologicals' meningococcal vaccine 134612 given at 12-15 months of age or at 15-18 months of age (co-administered with Infanrix®) in healthy toddlers primed with GSK Biological's Hib-meningococcal vaccine 792014. This study is single-blinded for the primary phase and open-label for the booster phase.
Detailed description
The purpose of this study is to evaluate the titer of antibody for serogroups A, C, Y and W-135 and the safety of a booster dose of GSK Biologicals' meningococcal vaccine 134612 given to toddlers who were primed with GSK Biological's Hib-meningococcal vaccine 792014. In addition, this study will provide immunogenicity and safety data on the co-administration of Infanrix with meningococcal vaccine 134612 as compared to Infanrix administered alone. Depending on the group the subject is assigned to, one or two blood samples will be taken out of the subject's arm during the study. The protocol posting has been updated following a protocol amendment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix) | One dose in the booster phase as intramuscular injection |
| BIOLOGICAL | GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix) | Three doses in the priming phase and, for Menhibrix 2 Group, one dose in the booster phase as intramuscular injection |
| BIOLOGICAL | Infanrix® | One dose as intramuscular injection |
| BIOLOGICAL | ActHIB® | Three doses in the priming phase as intramuscular injection |
| BIOLOGICAL | Pediarix® | Three doses in the priming phase as intramuscular injection |
Timeline
- Start date
- 2008-02-13
- Primary completion
- 2009-07-31
- Completion
- 2009-09-17
- First posted
- 2008-02-13
- Last updated
- 2018-09-21
- Results posted
- 2012-07-20
Locations
56 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00614614. Inclusion in this directory is not an endorsement.